VA researchers develop new treatment for liver disease
March 31, 2020
A VA research team led by Dr. Gianfranco Alpinini of the Richard L. Roudebush Indianapolis VA Medical Center created a new treatment for liver disease. Using mouse studies, the researchers found a compound that improves liver damage linked to several forms of liver disease. The drug could be used as a treatment for liver diseases such as primary sclerosing cholangitis, biliary atresia, and non-alcoholic fatty liver disease. Fatty liver disease is the most common type of liver disease in the Western world. VA has filed a patent for the treatment. Through Tech Transfer agreements, private businesses can now obtain rights to develop this research into life-saving medicines.
Drug shows promise in reducing deadly brain swelling after stroke
March 24, 2020
A new drug developed by VA and international partners could reduce deadly brain damage from stroke. The drug, ZT-1a, has proved effective at reducing brain swelling after stroke in animal models. It targets a pathway in the brain that controls how ions and water move in and out of brain cells. After stroke, malfunctioning proteins can allow too much water into the brain and cause dangerous swelling. ZT-1a stops these proteins from activating. Currently, invasive brain surgery is needed to alleviate this swelling. The drug was developed by an international consortium, including Dr. Dandan Sun of the VA Pittsburgh Health Care System. The consortium was made up of inventors from Xiamen University in China, Exeter University in the United Kingdom, and the VA and University of Pittsburgh. VA has filed a patent for the drug’s use as a stroke treatment.
Chip-based test for bleeding or clotting risk earns FDA ‘Breakthrough Device’ status
March 12, 2020
An experimental portable blood-clotting sensor called ClotChip, co-owned by VA and Case Western Reserve University and licensed to the private company XaTek, now has FDA “Breakthrough Device” status. The designation speeds the development of technologies that outperform current products in treating or diagnosing serious conditions. Investigators with VA’s Advanced Platform Technology Center and CWRU developed and tested the technology. It can assess a patient’s clotting ability—based on a single drop of blood—in about 15 minutes, compared with a day or longer for existing methods. “ClotChip is designed to minimize the time and effort for blood-sample preparation. [It can] be used at the doctor’s office or other points of care for patients on anticoagulation therapy [or] antiplatelet therapy, or who have suffered a traumatic injury causing bleeding,” said Dr. Pedram Mohseni in a 2016 CWRU article.
Patent for new way to treat dangerous hospital infection
February 25, 2020
(Photo courtesy of CDC)
VA and the University of Maryland are joint owners of a newly issued patent (US 10,537,609 B2) for a peptide-based treatment for Pseudomonas aeruginosa infections. P. aeruginosa can cause infections in the blood, lungs, or other parts of the body after surgery. At highest risk are hospital patients on breathing machines, those with catheters, and those with wounds from surgery or burns. The new potential treatment has been tested successfully in mice and is pending further study. The approach is promising because it uses a specific peptide, or a piece of a protein, to defeat the bacteria and does not rely on antibiotics. P. aeruginosa is increasingly resistant to antibiotics. In 2017, multidrug-resistant P. aeruginosa caused an estimated 32,6000 infections and 2,700 deaths in the U.S. Visit VA’s partner TechLink to read more about this and other available technologies based on VA inventions and discoveries.